ID   RIPK2_HUMAN             Reviewed;         540 AA.
AC   O43353; B7Z748; Q6UWF0;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 2.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Receptor-interacting serine/threonine-protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=CARD-containing interleukin-1 beta-converting enzyme-associated kinase;
DE            Short=CARD-containing IL-1 beta ICE-kinase;
DE   AltName: Full=RIP-like-interacting CLARP kinase;
DE   AltName: Full=Receptor-interacting protein 2;
DE            Short=RIP-2;
DE   AltName: Full=Tyrosine-protein kinase RIPK2;
DE            EC=2.7.10.2;
GN   Name=RIPK2; Synonyms=CARDIAK, RICK, RIP2;
GN   ORFNames=UNQ277/PRO314/PRO34092;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-47.
RX   PubMed=9575181; DOI=10.1074/jbc.273.20.12296;
RA   Inohara N., del Peso L., Koseki T., Chen S., Nunez G.;
RT   "RICK, a novel protein kinase containing a caspase recruitment domain,
RT   interacts with CLARP and regulates CD95-mediated apoptosis.";
RL   J. Biol. Chem. 273:12296-12300(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-47.
RC   TISSUE=Endothelial cell;
RX   PubMed=9642260; DOI=10.1074/jbc.273.27.16968;
RA   McCarthy J.V., Ni J., Dixit V.M.;
RT   "RIP2 is a novel NF-kappaB-activating and cell death-inducing
RT   kinase.";
RL   J. Biol. Chem. 273:16968-16975(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF ASP-146.
RC   TISSUE=Pancreatic adenocarcinoma;
RX   PubMed=9705938; DOI=10.1016/S0960-9822(07)00352-1;
RA   Thome M., Hofmann K., Burns K., Martinon F., Bodmer J.-L.,
RA   Mattmann C., Tschopp J.;
RT   "Identification of CARDIAK, a RIP-like kinase that associates with
RT   caspase-1.";
RL   Curr. Biol. 8:885-888(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=14638696; DOI=10.1074/jbc.C300460200;
RA   Ruefli-Brasse A.A., Lee W.P., Hurst S., Dixit V.M.;
RT   "Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-
RT   kappaB activation.";
RL   J. Biol. Chem. 279:1570-1574(2004).
RN   [9]
RP   PHOSPHORYLATION AT SER-176.
RX   PubMed=16824733; DOI=10.1016/j.cellsig.2006.05.005;
RA   Dorsch M., Wang A., Cheng H., Lu C., Bielecki A., Charron K.,
RA   Clauser K., Ren H., Polakiewicz R.D., Parsons T., Li P., Ocain T.,
RA   Xu Y.;
RT   "Identification of a regulatory autophosphorylation site in the
RT   serine-threonine kinase RIP2.";
RL   Cell. Signal. 18:2223-2229(2006).
RN   [10]
RP   FUNCTION, INTERACTION WITH NOD1, AND MUTAGENESIS OF ARG-444; ARG-483
RP   AND ARG-488.
RX   PubMed=17054981; DOI=10.1016/j.jmb.2006.09.067;
RA   Manon F., Favier A., Nunez G., Simorre J.P., Cusack S.;
RT   "Solution structure of NOD1 CARD and mutational analysis of its
RT   interaction with the CARD of downstream kinase RICK.";
RL   J. Mol. Biol. 365:160-174(2007).
RN   [11]
RP   INTERACTION WITH MAP3K4.
RX   PubMed=18775659; DOI=10.1016/j.cub.2008.07.084;
RA   Clark N.M., Marinis J.M., Cobb B.A., Abbott D.W.;
RT   "MEKK4 sequesters RIP2 to dictate NOD2 signal specificity.";
RL   Curr. Biol. 18:1402-1408(2008).
RN   [12]
RP   INTERACTION WITH IKBKG/NEMO AND MAP3K7/TAK1, FUNCTION, UBIQUITINATION
RP   AT LYS-209, AND MUTAGENESIS OF LYS-209.
RX   PubMed=18079694; DOI=10.1038/sj.emboj.7601962;
RA   Hasegawa M., Fujimoto Y., Lucas P.C., Nakano H., Fukase K., Nunez G.,
RA   Inohara N.;
RT   "A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-
RT   kappaB activation.";
RL   EMBO J. 27:373-383(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363; SER-527 AND
RP   SER-539, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-531, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   UBIQUITINATION BY ITCH, AND INTERACTION WITH NOD2.
RX   PubMed=19592251; DOI=10.1016/j.cub.2009.06.038;
RA   Tao M., Scacheri P.C., Marinis J.M., Harhaj E.W., Matesic L.E.,
RA   Abbott D.W.;
RT   "ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence
RT   inflammatory signaling pathways.";
RL   Curr. Biol. 19:1255-1263(2009).
RN   [16]
RP   UBIQUITINATION BY BIRC2 AND BIRC3.
RX   PubMed=19464198; DOI=10.1016/j.immuni.2009.04.011;
RA   Bertrand M.J., Doiron K., Labbe K., Korneluk R.G., Barker P.A.,
RA   Saleh M.;
RT   "Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for
RT   innate immunity signaling by the pattern recognition receptors NOD1
RT   and NOD2.";
RL   Immunity 30:789-801(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168; SER-363; SER-393;
RP   SER-527 AND SER-539, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   FUNCTION, PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474.
RX   PubMed=21123652; DOI=10.1101/gad.1964410;
RA   Tigno-Aranjuez J.T., Asara J.M., Abbott D.W.;
RT   "Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven
RT   cytokine responses.";
RL   Genes Dev. 24:2666-2677(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-529, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   UBIQUITINATION BY BIRC2/C-IAP1 AND BIRC3/C-IAP2, AND INTERACTION WITH
RP   BIRC2/C-IAP1; BIRC3/C-IAP2 AND XIAP/BIRC4.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R.,
RA   De Medts J., Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [22]
RP   INTERACTION WITH NLRP10.
RX   PubMed=22672233; DOI=10.1111/j.1462-5822.2012.01822.x;
RA   Lautz K., Damm A., Menning M., Wenger J., Adam A.C., Zigrino P.,
RA   Kremmer E., Kufer T.A.;
RT   "NLRP10 enhances Shigella-induced pro-inflammatory responses.";
RL   Cell. Microbiol. 14:1568-1583(2012).
RN   [23]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH ARHGEF2 AND NOD2,
RP   INTERACTION WITH ARHGEF2 AND NOD2, AND PHOSPHORYLATION AT TYR-381.
RX   PubMed=21887730; DOI=10.1002/ibd.21851;
RA   Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B.,
RA   Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.;
RT   "Control of NOD2 and Rip2-dependent innate immune activation by GEF-
RT   H1.";
RL   Inflamm. Bowel Dis. 18:603-612(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363; SER-527; SER-529
RP   AND SER-531, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   UBIQUITINATION, AND DEUBIQUITINATION.
RX   PubMed=23806334; DOI=10.1016/j.molcel.2013.06.004;
RA   Fiil B.K., Damgaard R.B., Wagner S.A., Keusekotten K., Fritsch M.,
RA   Bekker-Jensen S., Mailand N., Choudhary C., Komander D.,
RA   Gyrd-Hansen M.;
RT   "OTULIN restricts Met1-linked ubiquitination to control innate immune
RT   signaling.";
RL   Mol. Cell 50:818-830(2013).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-259; VAL-268 AND ASN-313.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine/tyrosine kinase that plays an essential
CC       role in modulation of innate and adaptive immune responses. Upon
CC       stimulation by bacterial peptidoglycans, NOD1 and NOD2 are
CC       activated, oligomerize and recruit RIPK2 through CARD-CARD
CC       domains. Contributes to the tyrosine phosphorylation of the
CC       guanine exchange factor ARHGEF2 through Src tyrosine kinase
CC       leading to NF-kappaB activation by NOD2. Once recruited, RIPK2
CC       autophosphorylates and undergoes 'Lys-63'-linked
CC       polyubiquitination by E3 ubiquitin ligases XIAP, BIRC2 and BIRC3.
CC       The polyubiquitinated protein mediates the recruitment of
CC       MAP3K7/TAK1 to IKBKG/NEMO and induces 'Lys-63'-linked
CC       polyubiquitination of IKBKG/NEMO and subsequent activation of
CC       IKBKB/IKKB. In turn, NF-kappa-B is released from NF-kappa-B
CC       inhibitors and translocates into the nucleus where it activates
CC       the transcription of hundreds of genes involved in immune
CC       response, growth control, or protection against apoptosis. Plays
CC       also a role during engagement of the T-cell receptor (TCR) in
CC       promoting BCL10 phosphorylation and subsequent NF-kappa-B
CC       activation. {ECO:0000269|PubMed:14638696,
CC       ECO:0000269|PubMed:17054981, ECO:0000269|PubMed:18079694,
CC       ECO:0000269|PubMed:21123652, ECO:0000269|PubMed:21887730}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10027}.
CC   -!- SUBUNIT: Found in a signaling complex consisting of at least
CC       ARHGEF2, NOD2 and RIPK2. Interacts with ARHGEF2; the interaction
CC       mediates tyrosine phosphorylation of RIPK2 by Src kinase CSK.
CC       Binds to CFLAR/CLARP and CASP1 via their CARD domains. Binds to
CC       BIRC3/c-IAP1 and BIRC2/c-IAP2, TRAF1, TRAF2, TRAF5 and TRAF6. May
CC       be a component of both the TNFRSF1A and TNRFSF5/CD40 receptor
CC       complex. Interacts with NOD1. Interacts (via CARD domain) with
CC       NOD2 (via CARD domain). Interacts with MAP3K4; this interaction
CC       sequesters RIPK2 from the NOD2 signaling pathway. Interacts with
CC       IKBKG/NEMO. The polyubiquitinated protein interacts with
CC       MAP3K7/TAK1. Interacts with XIAP/BIRC4. Interacts with NLRP10.
CC       Interacts with CARD9. {ECO:0000269|PubMed:17054981,
CC       ECO:0000269|PubMed:18079694, ECO:0000269|PubMed:18775659,
CC       ECO:0000269|PubMed:19592251, ECO:0000269|PubMed:21887730,
CC       ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:22672233}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-358522, EBI-358522;
CC       Q13490:BIRC2; NbExp=3; IntAct=EBI-358522, EBI-514538;
CC       Q13489:BIRC3; NbExp=3; IntAct=EBI-358522, EBI-517709;
CC       Q7Z434:MAVS; NbExp=3; IntAct=EBI-358522, EBI-995373;
CC       Q9HC29:NOD2; NbExp=2; IntAct=EBI-358522, EBI-7445625;
CC       Q13114:TRAF3; NbExp=5; IntAct=EBI-358522, EBI-357631;
CC       P98170:XIAP; NbExp=4; IntAct=EBI-358522, EBI-517127;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43353-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43353-2; Sequence=VSP_013266;
CC   -!- TISSUE SPECIFICITY: Detected in heart, brain, placenta, lung,
CC       peripheral blood leukocytes, spleen, kidney, testis, prostate,
CC       pancreas and lymph node.
CC   -!- DOMAIN: Contains an N-terminal kinase domain and a C-terminal
CC       caspase activation and recruitment domain (CARD) that mediates the
CC       recruitment of CARD-containing proteins.
CC   -!- PTM: Autophosphorylated. Autophosphorylation at Tyr-474 is
CC       necessary for effective NOD2 signaling. Phosphorylated.
CC       Phosphorylation at Tyr-381 by Src kinase CSK occurs in a ARHGEF2-
CC       dependent manner and is required for NOD2-dependent innate immune
CC       activation. {ECO:0000269|PubMed:16824733,
CC       ECO:0000269|PubMed:21123652, ECO:0000269|PubMed:21887730}.
CC   -!- PTM: Ubiquitinated on Lys-209; undergoes 'Lys-63'-linked
CC       polyubiquitination catalyzed by ITCH. Polyubiquitinated with 'Lys-
CC       48' and 'Lys-63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2,
CC       leading to activation of NF-kappa-B. Also undergoes 'Met-1'-linked
CC       polyubiquitination; the head-to-tail linear polyubiquitination is
CC       mediated by the LUBAC complex in response to NOD2 stimulation.
CC       Linear polyubiquitination is restricted by FAM105B/otulin,
CC       probably to limit NOD2-dependent proinflammatory signaling
CC       activation of NF-kappa-B. {ECO:0000269|PubMed:18079694,
CC       ECO:0000269|PubMed:19464198, ECO:0000269|PubMed:19592251,
CC       ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:23806334}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF027706; AAC34970.1; -; mRNA.
DR   EMBL; AF078530; AAC27722.1; -; mRNA.
DR   EMBL; AF064824; AAC25668.1; -; mRNA.
DR   EMBL; AY358813; AAQ89172.1; -; mRNA.
DR   EMBL; AY358814; AAQ89173.1; -; mRNA.
DR   EMBL; AK301448; BAH13484.1; -; mRNA.
DR   EMBL; AC004003; AAC24561.1; -; Genomic_DNA.
DR   EMBL; AF117829; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004553; AAH04553.1; -; mRNA.
DR   CCDS; CCDS6247.1; -. [O43353-1]
DR   RefSeq; NP_003812.1; NM_003821.5. [O43353-1]
DR   RefSeq; XP_005251149.1; XM_005251092.3. [O43353-2]
DR   UniGene; Hs.103755; -.
DR   PDB; 2N7Z; NMR; -; A=434-539.
DR   PDB; 2N83; NMR; -; B=434-539.
DR   PDB; 4C8B; X-ray; 2.75 A; A/B=8-317.
DR   PDB; 5AR2; X-ray; 2.44 A; A/B=1-310.
DR   PDB; 5AR3; X-ray; 3.23 A; A/B=1-310.
DR   PDB; 5AR4; X-ray; 2.70 A; A/B=1-310.
DR   PDB; 5AR5; X-ray; 2.66 A; A/B=1-310.
DR   PDB; 5AR7; X-ray; 2.71 A; A/B=1-310.
DR   PDB; 5AR8; X-ray; 2.79 A; A/B=1-310.
DR   PDB; 5J79; X-ray; 2.69 A; A/B=1-310.
DR   PDB; 5J7B; X-ray; 2.53 A; A/B=1-310.
DR   PDBsum; 2N7Z; -.
DR   PDBsum; 2N83; -.
DR   PDBsum; 4C8B; -.
DR   PDBsum; 5AR2; -.
DR   PDBsum; 5AR3; -.
DR   PDBsum; 5AR4; -.
DR   PDBsum; 5AR5; -.
DR   PDBsum; 5AR7; -.
DR   PDBsum; 5AR8; -.
DR   PDBsum; 5J79; -.
DR   PDBsum; 5J7B; -.
DR   ProteinModelPortal; O43353; -.
DR   SMR; O43353; -.
DR   BioGrid; 114300; 44.
DR   DIP; DIP-27518N; -.
DR   IntAct; O43353; 13.
DR   MINT; MINT-90752; -.
DR   STRING; 9606.ENSP00000220751; -.
DR   BindingDB; O43353; -.
DR   ChEMBL; CHEMBL5014; -.
DR   GuidetoPHARMACOLOGY; 2190; -.
DR   iPTMnet; O43353; -.
DR   PhosphoSitePlus; O43353; -.
DR   BioMuta; RIPK2; -.
DR   EPD; O43353; -.
DR   MaxQB; O43353; -.
DR   PaxDb; O43353; -.
DR   PeptideAtlas; O43353; -.
DR   PRIDE; O43353; -.
DR   DNASU; 8767; -.
DR   Ensembl; ENST00000220751; ENSP00000220751; ENSG00000104312. [O43353-1]
DR   GeneID; 8767; -.
DR   KEGG; hsa:8767; -.
DR   UCSC; uc003yee.4; human. [O43353-1]
DR   CTD; 8767; -.
DR   DisGeNET; 8767; -.
DR   GeneCards; RIPK2; -.
DR   HGNC; HGNC:10020; RIPK2.
DR   HPA; HPA015273; -.
DR   HPA; HPA016499; -.
DR   MIM; 603455; gene.
DR   neXtProt; NX_O43353; -.
DR   OpenTargets; ENSG00000104312; -.
DR   PharmGKB; PA34395; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00550000074536; -.
DR   HOGENOM; HOG000136856; -.
DR   HOVERGEN; HBG054242; -.
DR   InParanoid; O43353; -.
DR   KO; K08846; -.
DR   OMA; PFEEVIN; -.
DR   OrthoDB; EOG091G0505; -.
DR   PhylomeDB; O43353; -.
DR   TreeFam; TF106506; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   SignaLink; O43353; -.
DR   SIGNOR; O43353; -.
DR   ChiTaRS; RIPK2; human.
DR   GeneWiki; RIPK2; -.
DR   GenomeRNAi; 8767; -.
DR   PRO; PR:O43353; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000104312; -.
DR   CleanEx; HS_RIPK2; -.
DR   ExpressionAtlas; O43353; baseline and differential.
DR   Genevisible; O43353; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0050700; F:CARD domain binding; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030274; F:LIM domain binding; IPI:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; TAS:ProtInc.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IEA:Ensembl.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; IDA:UniProtKB.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IEA:Ensembl.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0070427; P:nucleotide-binding oligomerization domain containing 1 signaling pathway; IEA:Ensembl.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IEA:Ensembl.
DR   GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:MGI.
DR   GO; GO:0033091; P:positive regulation of immature T cell proliferation; IEA:Ensembl.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; NAS:BHF-UCL.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; NAS:BHF-UCL.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; NAS:BHF-UCL.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IMP:UniProtKB.
DR   GO; GO:0045627; P:positive regulation of T-helper 1 cell differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; NAS:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0070671; P:response to interleukin-12; IEA:Ensembl.
DR   GO; GO:0070673; P:response to interleukin-18; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0042098; P:T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IDA:MGI.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IEA:Ensembl.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017322; Rcpt-int_Ser/Thr_kinase-2.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00619; CARD; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF037921; STPK_RIP2; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Apoptosis;
KW   ATP-binding; Complete proteome; Cytoplasm; Immunity; Innate immunity;
KW   Isopeptide bond; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    540       Receptor-interacting serine/threonine-
FT                                protein kinase 2.
FT                                /FTId=PRO_0000086608.
FT   DOMAIN       18    294       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      432    524       CARD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   NP_BIND      24     32       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    146    146       Proton acceptor.
FT   BINDING      47     47       ATP.
FT   MOD_RES     168    168       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     176    176       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16824733}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     381    381       Phosphotyrosine; by CSK.
FT                                {ECO:0000269|PubMed:21887730}.
FT   MOD_RES     393    393       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     474    474       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:21123652}.
FT   MOD_RES     527    527       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     529    529       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     531    531       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     539    539       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   CROSSLNK    209    209       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18079694}.
FT   VAR_SEQ       1    137       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_013266.
FT   VARIANT     259    259       I -> T (in dbSNP:rs2230801).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041045.
FT   VARIANT     268    268       L -> V (in dbSNP:rs35004667).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041046.
FT   VARIANT     313    313       K -> N (in dbSNP:rs35395048).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041047.
FT   MUTAGEN      47     47       K->A: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:9575181,
FT                                ECO:0000269|PubMed:9642260}.
FT   MUTAGEN      47     47       K->M: Reduces FAS-mediated apoptosis.
FT                                {ECO:0000269|PubMed:9575181,
FT                                ECO:0000269|PubMed:9642260}.
FT   MUTAGEN     146    146       D->N: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:9705938}.
FT   MUTAGEN     209    209       K->R: Complete loss of
FT                                polyubiquitination.
FT                                {ECO:0000269|PubMed:18079694}.
FT   MUTAGEN     381    381       Y->A: Prevents phosphorylation. Reduces
FT                                serine and threonine phosphorylation of
FT                                ARHGEF2.
FT   MUTAGEN     444    444       R->E: Abolishes interaction with NOD1.
FT                                {ECO:0000269|PubMed:17054981}.
FT   MUTAGEN     474    474       Y->F: Decreases interaction with NOD2.
FT                                {ECO:0000269|PubMed:21123652}.
FT   MUTAGEN     483    483       R->E: Abolishes interaction with NOD1.
FT                                {ECO:0000269|PubMed:17054981}.
FT   MUTAGEN     488    488       R->E: Abolishes interaction with NOD1.
FT                                {ECO:0000269|PubMed:17054981}.
FT   CONFLICT    271    271       S -> G (in Ref. 5; BAH13484).
FT                                {ECO:0000305}.
FT   CONFLICT    514    514       Q -> R (in Ref. 5; BAH13484).
FT                                {ECO:0000305}.
FT   STRAND        7      9       {ECO:0000244|PDB:5AR2}.
FT   HELIX        15     17       {ECO:0000244|PDB:5AR2}.
FT   STRAND       18     25       {ECO:0000244|PDB:5AR2}.
FT   STRAND       31     37       {ECO:0000244|PDB:5AR2}.
FT   TURN         38     40       {ECO:0000244|PDB:5AR2}.
FT   STRAND       43     48       {ECO:0000244|PDB:5AR2}.
FT   HELIX        59     72       {ECO:0000244|PDB:5AR2}.
FT   STRAND       81     86       {ECO:0000244|PDB:5AR2}.
FT   STRAND       91     96       {ECO:0000244|PDB:5AR2}.
FT   HELIX       103    108       {ECO:0000244|PDB:5AR2}.
FT   TURN        110    112       {ECO:0000244|PDB:5AR2}.
FT   HELIX       118    136       {ECO:0000244|PDB:5AR2}.
FT   STRAND      138    140       {ECO:0000244|PDB:5AR2}.
FT   HELIX       149    151       {ECO:0000244|PDB:5AR2}.
FT   STRAND      152    154       {ECO:0000244|PDB:5AR2}.
FT   STRAND      160    162       {ECO:0000244|PDB:5AR2}.
FT   HELIX       190    192       {ECO:0000244|PDB:5J79}.
FT   HELIX       195    197       {ECO:0000244|PDB:5AR2}.
FT   TURN        202    204       {ECO:0000244|PDB:5AR4}.
FT   HELIX       210    224       {ECO:0000244|PDB:5AR2}.
FT   TURN        228    231       {ECO:0000244|PDB:5J79}.
FT   HELIX       235    243       {ECO:0000244|PDB:5AR2}.
FT   TURN        252    254       {ECO:0000244|PDB:5AR2}.
FT   HELIX       262    272       {ECO:0000244|PDB:5AR2}.
FT   HELIX       277    279       {ECO:0000244|PDB:5AR2}.
FT   HELIX       283    294       {ECO:0000244|PDB:5AR2}.
FT   HELIX       299    307       {ECO:0000244|PDB:5AR2}.
FT   HELIX       436    450       {ECO:0000244|PDB:2N7Z}.
FT   HELIX       453    465       {ECO:0000244|PDB:2N7Z}.
FT   HELIX       471    476       {ECO:0000244|PDB:2N7Z}.
FT   HELIX       483    497       {ECO:0000244|PDB:2N7Z}.
FT   HELIX       501    511       {ECO:0000244|PDB:2N7Z}.
FT   STRAND      526    528       {ECO:0000244|PDB:2N7Z}.
FT   TURN        530    532       {ECO:0000244|PDB:2N83}.
SQ   SEQUENCE   540 AA;  61195 MW;  575A692239505792 CRC64;
     MNGEAICSAL PTIPYHKLAD LRYLSRGASG TVSSARHADW RVQVAVKHLH IHTPLLDSER
     KDVLREAEIL HKARFSYILP ILGICNEPEF LGIVTEYMPN GSLNELLHRK TEYPDVAWPL
     RFRILHEIAL GVNYLHNMTP PLLHHDLKTQ NILLDNEFHV KIADFGLSKW RMMSLSQSRS
     SKSAPEGGTI IYMPPENYEP GQKSRASIKH DIYSYAVITW EVLSRKQPFE DVTNPLQIMY
     SVSQGHRPVI NEESLPYDIP HRARMISLIE SGWAQNPDER PSFLKCLIEL EPVLRTFEEI
     TFLEAVIQLK KTKLQSVSSA IHLCDKKKME LSLNIPVNHG PQEESCGSSQ LHENSGSPET
     SRSLPAPQDN DFLSRKAQDC YFMKLHHCPG NHSWDSTISG SQRAAFCDHK TTPCSSAIIN
     PLSTAGNSER LQPGIAQQWI QSKREDIVNQ MTEACLNQSL DALLSRDLIM KEDYELVSTK
     PTRTSKVRQL LDTTDIQGEE FAKVIVQKLK DNKQMGLQPY PEILVVSRSP SLNLLQNKSM
//
